Reviews of current literature studying natives in Australia, Brazil, Canada, and the United States from participants aged 45 to 94 years old reveal varied prevalence rates for cognitive impairment not related to dementia, from 4.4% to 17.7%. These results can be interpreted in the context of culturally biased neurocognitive tests, preexisting health conditions, poor access to healthcare, lower educational attainment, and/or old age. Sex
Women
Compared to their male counterparts, womens scores on the Mini Mental State Exam (MMSE) tend to decline at slightly faster rates with age. Males with mild cognitive impairment tend to show more microstructural damage than females with MCI, but seem to have a greater cognitive reserve due to larger absolute brain size and neuronal density. As a result, women tend to manifest symptoms of cognitive decline at lower thresholds than men do. This effect seems to be moderated by educational attainment - higher education is associated with later diagnosis of mild cognitive impairment as neuropathological load increases. Transgender Individuals
LGBT elders face numerous disparities as they approach end-of-life. The transgender community fears the risk of hate crime, elder abuse, homelessness, loss of identity, and loss of independence as they age. As a result, depression and suicidality are particularly high within the demographic. Intersectionality - the overlap of several minority identities - can play a major role in health outcomes, as transgender people can be discriminated against for their race, sexuality, gender identity, and age.
Although different diagnostic criteria are published, a commonly used strategy to diagnose patients is to use all three of the following:

Symptoms consistent with chronic/recurrent mast cell release:  Recurrent abdominal pain, diarrhea, flushing, itching, nasal congestion, coughing, chest tightness, wheezing, lightheadedness (usually a combination of some of these symptoms is present)
Laboratory evidence of mast cell mediator (elevated serum tryptase, N-methyl histamine, prostaglandin D2 or 11-beta- prostaglandin F2 alpha, leukotriene E4 and others)
Improvement in symptoms with the use of medications that block or treat elevations in these mediators"The World Health Organization has not published diagnostic criteria. Treatment
Common pharmacological treatments include:

Mast cell stabilizers, including cromolyn sodium and natural stabilizers such as quercetin
H1-antihistamines, such as cetirizine or ketotifen or fexofenadine or loratadine
H2-antihistamines, such as ranitidine or famotidine
Antileukotrienes, such as montelukast or zileuton as well as natural products (e.g., curcumin or St. Johns wort extracts)
Nonsteroidal anti-inflammatory drugs, including aspirin can be very helpful in reducing inflammation in some patients, while others can have dangerous reactions

Prognosis
The prognosis of MCAS is uncertain because of lack of studies. History
The condition was hypothesized by the pharmacologists John Oates and Jack Roberts of Vanderbilt University in 1991, and following a build-up of evidence featured in papers by Sonneck et al. and Akin et al., named in 2007.Diagnostic criteria were proposed in 2010 and revised in 2019. See also
FcεRI
Histamine intolerance
Immunoglobulin E

References


== External links ==